MCL Literature Feed

Quantifying the survival cost of delayed CAR T-cell reimbursement in Europe shows faster access for MCL patients would translate directly into more lives and life-years saved.

A case report demonstrates that MCL can relapse in rare sites like skeletal muscle after rituximab maintenance, underscoring the value of PET/CT for detecting atypical disease progression.

Single-cell RNA sequencing reveals pre-existing, minor therapy-resistant subclones at diagnosis, which are selected during treatment, explaining early relapse and highlighting cell-cycle dysregulation as a common resistance mechanism.

In real-world relapsed/refractory MCL, ibrutinib dose reduction to manage toxicity is common and does not compromise response rates, PFS, or OS, validating this as a practical clinical strategy.

PRMT5 inhibition sensitizes MCL cells to ferroptosis by disrupting the ATF5-SLC7A11 axis, providing a rationale for combining PRMT5 inhibitors with ferroptosis inducers for relapsed/refractory disease.

Single-cell multi-omics reveals genetic and non-genetic pirtobrutinib resistance mechanisms in MCL, identifying the cohesin complex as a potential target to restore drug sensitivity.

Consensus guidelines recommend the BOVen triplet (zanubrutinib, obinutuzumab, venetoclax) for TP53-mutated MCL and CAR-T for BTKi-refractory disease, providing expert guidance for managing high-risk patients.

This review outlines the evolving MCL treatment paradigm, detailing the integration of BTKi, CAR-T, and bispecific antibodies in both frontline and relapsed/refractory settings to improve patient outcomes.

Genomic analysis reveals MCL relapse is driven by the expansion of pre-existing resistant subclones, not new mutations, highlighting the need for deep sequencing at diagnosis to prevent recurrence.

This retrospective analysis evaluates transplant outcomes in relapsed/refractory MCL after ibrutinib failure, identifying risk factors to guide patient selection for this intensive consolidation therapy.

In a resource-limited setting, 12% of chemosensitive MCL patients progress by 3 months while awaiting autologous transplant, highlighting the need for prioritization and defining acceptable wait times.

Real-world data from Germany and Switzerland confirms the effectiveness of brexucabtagene-autoleucel in relapsed/refractory MCL, supporting its use in routine clinical practice beyond trial populations.

This review outlines evidence for sequencing BTKis, CAR-T, and bispecifics in relapsed/refractory MCL, a growing challenge as targeted therapies are increasingly used in the frontline setting.

This UK real-world study shows chemotherapy bridging before brexu-cel yields higher responses than targeted therapy but causes more toxicity and early mortality without improving post-CAR-T survival.

Brexucabtagene autoleucel demonstrates high efficacy (91% ORR, 73% CR) in BTKi-naive relapsed/refractory MCL, supporting its use as an effective option before BTKi failure in high-risk patients.

The novel BCL-2 inhibitor lisaftoclax demonstrated a 50% overall response rate and manageable safety in a phase 1 trial of Chinese patients with relapsed/refractory MCL.

This German real-world study (2015-2020) reveals rising MCL incidence and poor outcomes, highlighting a dismal median OS of 3.0 months after cBTKi discontinuation, underscoring a critical unmet need.

Dual inhibition of anti-apoptotic proteins BIRC5 and MCL-1 is a novel preclinical strategy to overcome drug resistance in mantle cell lymphoma, offering a potential new therapeutic avenue.

In a real-world R/R MCL cohort, zanubrutinib demonstrated significantly longer overall survival versus ibrutinib and favorable trends versus acalabrutinib, guiding clinical selection of covalent BTKis.

This meta-analysis suggests zanubrutinib monotherapy yields superior complete and overall response rates over ibrutinib and acalabrutinib in relapsed/refractory MCL, informing optimal BTKi selection.

In a large real-world cohort, brexu-cel demonstrated high efficacy in R/R MCL patients ≥70 years, indicating functional status, not chronological age, should determine CAR-T eligibility.

The oral AKT inhibitor capivasertib showed modest single-agent activity (30% ORR) in relapsed/refractory MCL, with PTEN deficiency emerging as a potential predictive biomarker for patient selection.

Bridging radiotherapy before CAR-T effectively controls disease in MCL patients, with most showing rapid tumor reduction and no local progression, supporting its use as a pre-CAR-T strategy.

This real-world study identifies key patient and systemic barriers limiting CAR-T therapy access for relapsed/refractory MCL, highlighting disparities between trial eligibility and clinical practice.

This review provides a treatment and sequencing algorithm for relapsed/refractory MCL, navigating the complex landscape of BTKi, BCL2i, CAR-T, bispecifics, and transplant for individualized patient care.

This longitudinal study reveals MCL acquires new high-risk genetic features after chemoimmunotherapy, explaining relapse and emphasizing the need for genomic profiling to guide subsequent therapies.

The CD19 CAR-T therapy relma-cel demonstrated high, durable responses (71% ORR, 18-month DOR) with manageable toxicity in heavily pretreated Chinese patients, establishing it as an effective option for relapsed/refractory MCL.

In a retrospective ZUMA-2 analysis, prior ibrutinib exposure, versus acalabrutinib, improved brexu-cel CAR-T efficacy and PFS by inducing a more favorable cytotoxic T-cell phenotype.

This US real-world study describes treatment patterns and outcomes for covalent BTK inhibitors in relapsed/refractory MCL, providing crucial benchmarks for routine clinical practice outside of trial settings.

This real-world study shows bendamustine-rituximab is the most common frontline therapy and BTK inhibitors for second-line, but median overall survival plummets in later lines, highlighting significant unmet need.